This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Late Winners & Losers

Theravance (THRX - Get Report) leapt 16% in after-hours trading Monday as the California-based biotech announced positive results in collaboration with GlaxoSmithKline (GSK - Get Report) from a phase IIb study of asthmatic patients.

Two proposed bronchodilator compounds -- one discovered by Theravance and the other by GlaxoSmith -- were both shown to induce "clinically significant increases in bronchodilation" (opening of the patients' airways) at least equal to the effects of salmeterol, an existing asthma treatment. Theravance shares were rising $4.75 to $34.75. GlaxoSmith was down 19 cents to $55 in recent late trading.

iRobot (IRBT - Get Report) gained on news of another $14 million order from the Naval Sea Systems Command for its PackBot bomb-disposing robots, part of which has already shipped. The order was placed under a pre-existing contract for up to $264 million in robots, spare parts and services good through 2012. Shares were gaining 91 cents, or 6.9%, to $14.10.

Lawson Software (LWSN) said fiscal third-quarter earnings should be higher than prior guidance of 2 cents to 3 cents a share (on a non-GAAP basis); revenue should range between $190 million and $192 million, excluding $1.8 million in deferred maintenance and service revenue. Analysts polled by Thomson Financial are looking for 3 cents a share on revenue of $187.2 million. Shares were up 47 cents, or 5.9%, to $8.50.

MTR Gaming (MNTG) posted fiscal fourth-quarter profits of $518,000, or 2 cents a share, compared with break-even last year. Revenue added 5.2% to $86.7 million, just edging out two analysts' estimates. Shares of the Chester, W.Va., company were gaining 64 cents, or 4.9%, to $13.66.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ZVUE $0.00 0.00%
MNTG $4.43 0.91%
GSK $40.96 0.00%
IRBT $33.07 0.00%
THRX $9.08 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs